Thomas Jefferson University

Jefferson Digital Commons
Department of Neurology Faculty Papers

Department of Neurology

1-14-2022

Atypical Ataxia Presentation in Variant Ataxia Telangiectasia:
Iranian Case-Series and Review of the Literature
Tannaz Moeini Shad
Reza Yazdani
Parisa Amirifar
Samaneh Delavari
Marzieh Heidarzadeh Arani

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp
Part of the Neurology Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Tannaz Moeini Shad, Reza Yazdani, Parisa Amirifar, Samaneh Delavari, Marzieh Heidarzadeh Arani, Seyed
Alireza Mahdaviani, Mahnaz Sadeghi-Shabestari, Asghar Aghamohammadi, Nima Rezaei, and Hassan
Abolhassani

SYSTEMATIC REVIEW
published: 14 January 2022
doi: 10.3389/fimmu.2021.779502

Atypical Ataxia Presentation in
Variant Ataxia Telangiectasia:
Iranian Case-Series and Review
of the Literature
Tannaz Moeini Shad 1,2, Reza Yazdani 1,2,3*, Parisa Amirifar 1,4, Samaneh Delavari 1,2,
Marzieh Heidarzadeh Arani 5, Seyed Alireza Mahdaviani 6, Mahnaz Sadeghi-Shabestari 7,
Asghar Aghamohammadi 1, Nima Rezaei 1,2,8 and Hassan Abolhassani 1,2,9,10*
1

Edited by:
Antonio Condino-Neto,
University of São Paulo, Brazil
Reviewed by:
Mauro Magnani,
University of Urbino Carlo Bo, Italy
Claudio Pignata,
University of Naples Federico II, Italy
*Correspondence:
Reza Yazdani
reza_yazdani86@yahoo.com
Hassan Abolhassani
hassan.abolhassani@ki.se
Specialty section:
This article was submitted to
Primary Immunodeﬁciencies,
a section of the journal
Frontiers in Immunology
Received: 18 September 2021
Accepted: 23 December 2021
Published: 14 January 2022
Citation:
Moeini Shad T, Yazdani R,
Amirifar P, Delavari S,
Heidarzadeh Arani M, Mahdaviani SA,
Sadeghi-Shabestari M,
Aghamohammadi A, Rezaei N and
Abolhassani H (2022) Atypical Ataxia
Presentation in Variant Ataxia
Telangiectasia: Iranian Case-Series
and Review of the Literature.
Front. Immunol. 12:779502.
doi: 10.3389/fimmu.2021.779502

Research Center for Immunodeﬁciencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of
Medical Sciences, Tehran, Iran, 2 Primary Immunodeﬁciency Diseases Network (PIDNet), Universal Scientiﬁc Education and
Research Network (USERN), Tehran, Iran, 3 Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United
States, 4 Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran,
5 Department of Asthma, Allergy & Immunology, Kashan University of Medical Sciences, Kashan, Iran, 6 Pediatric Respiratory
Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti
University of Medical Sciences, Tehran, Iran, 7 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz,
Iran, 8 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientiﬁc Education and Research
Network (USERN), Tehran, Iran, 9 Division of Clinical Immunology, Department of Biosciences and Nutrition, Karolinska
Institutet, Huddinge, Sweden, 10 Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at
Karolinska University Hospital Huddinge, Stockholm, Sweden

Ataxia-telangiectasia (AT) is a rare autosomal recessive neurodegenerative multisystem
disorder. A minority of AT patients can present late-onset atypical presentations due to
unknown mechanisms. The demographic, clinical, immunological and genetic data were
collected by direct interview and examining the Iranian AT patients with late-onset
manifestations. We also conducted a systematic literature review for reported atypical
AT patients. We identiﬁed three Iranian AT patients (3/249, 1.2% of total registry) with later
age at ataxia onset and slower neurologic progression despite elevated alpha-fetoprotein
levels, history of respiratory infections, and immunological features of the syndrome. Of
note, all patients developed autoimmunity in which a decrease of naïve T cells and
regulatory T cells were observed. The literature searches also summarized data from 73
variant AT patients with atypical presentation indicating biallelic mild mutations mainly lead
to an atypical phenotype with an increased risk of cancer. Variant AT patients present with
milder phenotype or atypical form of classical symptoms causing under- or misdiagnosis. Although missense mutations are more frequent, an atypical presentation
can be associated with deleterious mutations due to unknown modifying factors.
Keywords: primary immunodeﬁciency, inborn errors of immunity, ataxia-telangiectasia, late-ataxia, atypical
presentation, mild phenotype, autoimmunity
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the principles of the ethics committee of the Tehran University of
Medical Sciences (12, 14). Diagnosis of the patients was based on
the European Society for Immunodeﬁciency (ESID) guideline
(15), including ataxia and at least two of the following:
oculocutaneous telangiectasia, elevated AFP, lymphocyte AT
karyotype with translocation chromosome 7:14, and cerebellar
hypoplasia on magnetic resonance imaging (MRI). The wholeexome sequencing and conﬁrmatory Sanger sequencing method
were carried out according to a pipeline published previously
(16–20), and a radiosensitivity test using G0 and G2 phase assays
on phytohemagglutinin (PHA) stimulated peripheral blood
lymphocytes were performed (21).

INTRODUCTION
Ataxia-telangiectasia (AT) is a rare autosomal recessive
multisystem disorder caused by mutations in the ataxia
telangiectasia mutated (ATM) gene encoding a protein kinase
with a key role in the cell cycle control and DNA repair (1, 2).
Given the residual kinase activity and the type of ATM mutation,
the clinical spectrum of AT varies from a severe (early-onset and
rapidly progressing neurodegeneration classic) phenotype to a
variant atypical form (a relatively mild neurological phenotype
and a lower risk of systemic complications) (3).
Classical AT is characterized by early childhood-onset
cerebellar ataxia, telangiectasia, immunodeﬁciency, increased
serum alpha-fetoprotein (AFP) levels, autoimmune or other
chronic inﬂammatory diseases, radiosensitivity, and increased
susceptibility to malignancies. Most children are usually
wheelchair-bound by age 10 years and die in the second
decade of life due to malignancies or respiratory failure (4–6).
In contrast to the classical AT group, variant AT patients with
milder late-onset atypical phenotypes characterized by a
predominance of extrapyramidal features (instead of
cerebellar), late ataxia onset, slower neurologic progression
with a mild phenotype, and an extended lifespan. Respiratory
diseases and immunodeﬁciency are less severe in variant AT;
however, the risk of malignancy is likely high, and such patients
may also be radiosensitive (7–9). Overall, the classical form is
caused by biallelic deleterious ATM mutations, which lead to a
total loss of ATM protein, while majority of patients with milder
phenotypes carry at least one missense or leaky splice site
mutation (still producing the protein with residual function or
kinase activity) (8). Moreover, some reports suggest that besides
residual ATM kinase activity, other factors such as modifying
genes and environmental factors might be involved in the
presentation of milder phenotypes of AT (10).
Here, we describe three Iranian AT patients with variant
atypical phenotypes who presented late-onset manifestations and
developed autoimmunity in the course of the disease. For the ﬁrst
time, we reviewed systematically the literature of all previously
reported AT atypical patients who had non-ataxia dominant
signs or had late-onset ataxia presentation to illustrate a
comprehensive picture of the milder AT phenotype.

Search Strategy for Reported Variant
AT Patients
The literature searches for all reported atypical AT patients who
had no dominant ataxia signs or had late-onset (≥ 5 years) ataxia
reported up to September 1, 2021, was conducted by PubMed,
Web of Science, and Scopus databases, applying the following
keywords: “ataxia-telangiectasia” OR its synonyms (“ATM” OR
“Louis-Bar syndrome”) in combination with terms for unusual
ataxia presentation (including “late-onset” OR “variant” OR
“adolescence” OR “atypical” OR “mild”). The articles were ﬁrst
screened based on the title and abstract to exclude all irrelevant
studies, and then their full-text manuscripts were assessed for
eligibility criteria (written in English, conducted on human
subjects, reporting at least one patient with unusual ataxia
presentation and detailed description of genetic, clinical, and
immunological features). A manual search of bibliographies of
the retrieved publications was performed to identify additional
relevant studies (Supplementary Figure 1). All cases were
categorized into three neurological phenotypic groups, based
on the presence of ataxia and using a wheelchair. Group I, Mild
for patients without dominant ataxic signs. Group II, Moderate
for patients who developed late ataxia but without being
wheelchair-bound. Group III, Severe for patients who
developed late ataxia and used a wheelchair. Central and
descriptive statistics were reported for quantitative data. For
variables with non-normal distribution, median and interquartile
ranges (IQR) were reported. All statistical tests were 2 tailed, and
a P-value of less than 0.05 was considered statistically signiﬁcant.
All statistical analyses were performed using the SPSS software
(v. 26.0, Chicago, IL).

MATERIALS AND METHODS
Patients and Clinical Evaluation

RESULTS

Data of new patients including demographic data, medical
history, and physical examination, were collected by medical
records through national consensus on diagnosis and
management guidelines for primary immunodeﬁciency (PID)
(11). Demographic data included age, gender, age at disease
onset, and age of diagnosis. The laboratory data were complete
cell blood counts, serum AFP level, T- and B-cells subsets, and
serum levels of immunoglobulins as previously described (12,
13). Medical information was collected after obtaining written
informed consent from the patients and their parents, following
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New Case Presentations
The ﬁrst atypical AT patient in the Iranian PID registry is a 9year-old boy, the only child of a consanguineous parent. The
patient had a healthy situation until nine months and then he
was referred to the Children’s Medical Center, Tehran, Iran, due
to recurrent respiratory infections. In the maternal branch of the
pedigree, typical AT was evident in his cousin. The patient
manifested several episodes of oral aphthous during the ﬁrst
year of age, but it was not further evaluated. At the age of 1 year,
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thigh skin lesion and bone marrow biopsy revealed
granulomatous inﬂammation (Figure 1A). At this age, she
presented ataxic gait and telangiectasia as well as
splenomegaly. Further neurological examination demonstrated
strabismus and a slight head and trunk tremor, as well as
dystonia and dysarthria. Increased AFP and presence of a
homozygous large deletion variant spanning in exons 37–48 of
the ATM gene conﬁrmed diagnosis of AT at the age of 12 years.
Immunologic and laboratory data are mentioned in detail in
Supplementary Table 1. At this age, she had an eye infection,
otitis media, and hearing loss. Unfortunately, the patient
deceased at the age of 13 due to respiratory infections, despite
mild neurological complications.
The third patient recorded is a 24-year-old female who was
born full term as the third child of a consanguineous parent with
no complications. Family history was remarkable for the second
16-year-old brother, who died because of a pulmonary infection as
a result of AT. As the ﬁrst clinical manifestation, the case
presented a moderate ataxic gait and mild ocular telangiectasia
at the age of 8 years, while other neurological examinations were
normal. Due to disability in movement and dysarthria, she had to
leave her education at 12 years of age. She was fully immunized
with no complications by the age of 22 years. At this age, she
presented with stable, severe, itchy, and quite sore plaques covered
by scaly lesions. Several topical treatments were ineffective over the
past year. Skin biopsy showed psoriasis disease (Figure 1B), and
she started to receive adalimumab injection (loading by 80 mg

he initiated walking without ataxia. Five months later, he was
hospitalized due to a 10-day fever and neutropenia and suspected
to Kawasaki disease, and treatment with intravenous
immunoglobulin (IVIG) 400 mg/kg for 3 weeks was started.
Over the ﬁrst 2 years of his life, he was also admitted 3 times due
to fever and acute sinusitis. At the age of 3 years, he presented
petechiae and bleeding in the oral cavity due to idiopathic
thrombocytopenic purpura (ITP), well responded to IVIG and
corticosteroids. The patient was hospitalized for one week
because of chickenpox and neutropenia at the age of 4 years. A
diagnosis of AT was fulﬁlled by presenting clinical
manifestations (ataxia, nystagmus, and ocular telangiectasia),
laboratory ﬁndings (increased serum AFP) and genetic testing
(a homozygous c.3895delG, p.A1299Pfs*50; frameshift mutation
of the ATM gene) at the age of 6 years. Other immunologic and
laboratory data are provided in Supplementary Table 1. At 7
years of age, the patient was hospitalized for parotitis, and
presented skin vesicular lesions and shingles. He was
discharged after the successful treatment of herpes zoster and
his neurologic status is stable without prophylactic treatment.
The second patient is a 13-year-old girl, with a history of
parental consanguinity without immunodeﬁciency in her family,
and she had normal developmental milestones. At the age of 3
years, she was admitted to the hospital due to thrombocytopenia,
spontaneous bruising, and purpura. She was diagnosed with ITP,
and then was treated with prednisolone for two years. At the age
of 6 years, she was hospitalized due to worsening skin lesions. A

A

B

FIGURE 1 | (A) Cutaneous granulomatous lesions on the extremities (Case 2); (B) extensive skin lesions of plaque psoriasis, which coalesce to cover almost the
whole of the body surface (Case 3).
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then followed by 40 mg every other week since week 1).
Laboratory tests showed diminished levels of IgA and an
elevated AFP level (411 mg/dL mg/dL). She also showed
increased radiosensitivity. Data of other immunological ﬁndings
are summarized in Supplementary Table 1. The diagnosis of AT
was conﬁrmed by identifying a homozygous stop-gain mutation
(c.6658C>T, p.Q2220*). Currently, the patient is ambulant, does
not require walking aids, and is maintaining the same clinical and
laboratory conditions.
Of note, none of these patients have other damaging
mutations in correct inheritance patterns in other known PID
genes classiﬁed based on the International Union of
Immunological Societies (IUIS) expert committee (22, 23).

22% (n=16) of patients had no dominant ataxic signs. In the severe
group, the median (IQR) age at onset of ataxia was signiﬁcantly
lower than the moderate group [8 (6.5-13) vs. 27 (17-33) years,
p=0.001]. Among recorded neurological complications, dysarthria
(64%), dystonia (49%), chorea (28%), and tremors (38%) were the
most common. Oculomotor abnormalities in the form of saccades
and oculomotor apraxia have been observed in 15% and 24.7%,
respectively. Seven individuals got their ﬁrst wheelchair within 1020 years of symptom onset, while 6 cases required it after 20 years.
Approximately 75% of patients presented extrapyramidal features
including dystonia, tremors, and chorea movements. Cerebellar
atrophy was found in 35 (65%) individuals at age of 28 (22-31) years,
while 19 cases demonstrated normal imaging of the cerebellum.
Expectedly, the frequency of cerebellar atrophy was higher in the
severe group (83.8%) than the moderate (70.3%; p=0.6) and mild
(38.4%; p=0.01) groups. Comparison of neurological features of the
73 described variant AT patients is illustrated in Figure 2.

Literature Review and Demographic
Features of Atypical AT Patients
Our literature search revealed 73 variant AT patients with
unusual ataxia phenotype (58% females) (Supplementary
Tables 2, 3). The median (IQR) age at onset was 11 (5.7-17)
years, as males had a slightly earlier age onset of 10 (6 -22) years
compared with females 12 (1.2-17) years. The ﬁrst presentation
of one-third of patients (29%) was after age 14 years, while 9
patients had the ﬁrst presentation after 20 years of age. A
minority of patients were classiﬁed in the mild group (n=16),
however moderate (n=32) and severe (n=19) cases were more
frequent. Classiﬁcation of disease severity was not available for
six cases due to a lack of data. Atypical patients in the severe
group had signiﬁcantly lower median (IQR) age of disease onset
6.5 (2.3-9.7) years compared to moderate 17 (6-29.5, p=0.001)
years, and mild 11 (2.6-16.5, p=0.04) years, groups.

Clinical and Immunological Features of
Atypical AT Patients
Comparisons of clinical features of the 73 described variant
atypical AT patients in 3 groups are illustrated in Table 1 and
Figure 3. Among 61 clinical recorded presentations, the most
prevalent ﬁrst presentation was neurologic symptoms in 56
(92%) of patients, with a median age of 10 (6 -17) years.
Recurrent infections as the ﬁrst presentation of the disease
were reported in only 5 patients (8%) with a median (IQR) age
of 1.5 (0 -7.5) years. Sixteen patients developed a malignancy
(solid tumors, 53%; lymphoma, 40%) mostly in adulthood with a
median (IQR) age of 37.5 (17 -55.5) years. Seven patients died
owing to malignancy, as four cases (P44, P56, P27, P43) with
solid tumors, two (P45, P53) due to leukemia, and one case (P11)
resulting from lymphoma. The most common type of
malignancy was lymphoma, leukemia and breast cancer.

Neurological features of Atypical AT Patients
Late presentation of cerebellar ataxia was presented in 78% (n=57)
patients with a median (IQR) age at onset of 13 (7- 28) years, while

FIGURE 2 | Comparison of neurological features of the 73 described variant AT patients.
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TABLE 1 | Comparison of demographic, clinical, laboratory and molecular features in 3 groups.
Parameter

Number of individuals
Male/Female
Presenting features
Median (IQR) age at onset, y
Median (IQR) age at onset of ataxia, y
Median (IQR) age at ﬁrst wheelchair
Telangiectasia, N (%)
Immunodeﬁciency, N (%)
Recurrent infections, N (%)
Karyotype abnormalities, N (%)
Cerebellar Atrophy (MRI), N (%)
Malignancy, N (%)
Median (IQR) AFP (microgram/L)
Chromosomal radio-sensitivity, N (%)
Severity based on mutation, N (%)
Severity based on ATM activity, N (%)
Heredity (HMZ/HTZ), N (%)

All patients

Group 1: Mild (- ataxia,
-Wheelchair)

Group 2: Moderate (+ ataxia,
-Wheelchair)

Group 3: Severe
(+ ataxia, +Wheelchair)

73
22/58
5 Recurrent infections
51 Neurologic problem
9(5.7-17)
13 (7.2-27.7)
18 (13.5-30)
42 (58)
28 (40)
10 (14)
33 (77)
35 (65)
12 (21)
120 (68-255)
26 (79)
58 (91) mild
6 (9) severe
32 (75) mild
11 (25) severe
21 (34)/40 (66)

16
6/10
4 Recurrent infections
11 Neurologic problem
11 (2.6-16.5)
–
–
7 (41.2)
10 (62.5)
5 (29.4)
6 (85.7)
5 (38.4)
5 (29.4)
118.5 (80.8-238.7)
9 (81.8)
12 (85.7) mild
2 (14.2) severe
7 (70) mild
3 (30) severe
7 (54)/6 (46)

32
12/11
- Recurrent infections
22 Neurologic problem
17(6-29.5)
27 (17-33)
–
18 (58.1)
11 (55)
–
16 (80)
19 (70.3)
5 (16.1)
115 (23.5-246.7)
11 (73.3)
27 (93.1) mild
2 (6.8) severe
16 (84.2) mild
3 (15.7) severe
7 (24)/22 (76)

19
3/7
- Recurrent infections
17 Neurologic problem
6.5 (2.3-9.7)
8 (6.5-13)
18 (13.5-30)
12 (63.2)
2 (12.5)
3 (15.8)
7 (63.6)
10 (83.8)
3 (15.8)
127 (89.7-270.7)
5 (83)
15 (93.7) mild
1 (6.2) severe
7 (87.5) mild
1 (12.5) severe
6 (40)/9 (60)

HMZ; homozygous, HTZ; compound heterozygous, Y; year, AFP; alpha fetoprotein, IQR; interquartile range, MRI: magnetic resonance imaging, N; Count.

FIGURE 3 | Comparison of clinical features of the 73 described variant AT patients in 3 groups.

rearrangements of chromosomes 7 and 14 were demonstrated.
Surprisingly, the frequency of abnormal karyotype in the mild
group (85.7%) was slightly higher than other groups (moderate,
80%; severe, 63.6%); however, the differences were not
signiﬁcant (p=0.41).
Genetic diagnosis based on ATM gene mutation was available
for 61 patients and revealed that 40 out of 61 patients (66%) had
a compound heterozygous mutation as well as homozygous
mutations were found in 21 patients (34%). Missense
mutations were the most prevalent, making up 60.6% of
all mutations, followed by splice site (14%), frameshift (13%),
and nonsense (9%) variants. Approximately 85% of patients
carried at least 1 missense mutation. Severe mutations,
including frameshift and/or nonsense for both alleles, were

Autoimmunity and granulomatous lesion were observed in two
patients (P73 and P1, respectively). Conjunctival telangiectasia
was observed in 42 individuals with documented assessment
(58%). The frequency of telangiectasia in the mild group (41%)
was lower than the moderate (58%) and severe (63%) groups;
however, the differences were not signiﬁcant (p=0.18). In terms
of the immunologic proﬁle, 71% had IgA deﬁciency, followed by
IgG subclass deﬁciency (19%) and hyper IgM phenotype (10%).

Genetic Characteristics of Atypical
AT Patients
Chromosomal radiosensitivity was normal in 7/33 individuals
tested (21%), while 26/33 (79%) cases demonstrated
chromosomal radiosensitivity. In 33 patients (77%), typical
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seen in only 6 (9%) patients; however mild alterations, including
missense alterations for at least one allele, were documented in
58 (91%) patients. A comparison of genetic characteristics of the
61 described variant AT patients is provided in Figure 4.

and P27 (p.R1730L and p.2862del29aa), despite low protein
expression, no residual ATM kinase activity was detected. The
distribution of known ATM mutations reported in the published
study is depicted in Figure 5.

Functional ATM Analyses in Atypical
AT Patients

DISCUSSION

ATM protein expression was detected in 36/44 atypical patients
tested (82%) of whom 5 cases showed normal ATM expression.
Residual ATM kinase activity was observed in 23/25 patients tested,
all with missense or splice site (splice only in patients P54 and P55)
mutations (Supplementary Table 3). Despite the mild mutations in
some selected patients (P1, P22, and P23), no protein expression
was observed. Moreover, in patients P26 (p.A2524P, p.W1221X)

Here we reported 3 variant atypical Iranian AT cases (1.2% of
total 249 AT patients registered in the national database of
primary immunodeﬁciency) with late-onset of ataxia despite
the presence of homozygous deleterious ATM mutation.
Surprisingly, all of these cases presented autoimmune
disorders. Moreover, for the ﬁrst time, we comprehensively

FIGURE 4 | Comparison of genetics characteristics of the 61 described variant AT patients.
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FIGURE 5 | Distribution of known ATM mutations in different variant AT patients. The ﬁgure shows a schematic presentation of the ATM protein with the relative
location of functionally important domains and the total mutations reported in the study (our 3 reported cases are indicated by red color). TAN; Tel1/ATM N-terminal
motif, SB; substrate binding, LZ; leucine zipper, P rich proline-rich, FAT; FRAP-ATM-TRRAP domain, ATP; ATP binding site, PI3K; phosphatidylinositol 3-kinaserelated kinase domain, FATC; FAT C-terminal domain (24–46).

and rarely develops as a presenting feature in AT patients (49).
Incompatible with a report by Mé neret et al. (50), in which
dystonia was the presenting feature in 14% of variant patients,
only 5% of reported variant atypical AT patients in our literature
review presented with dystonia. As observed in our 3 cases, the
majority of reported patients showed neurological abnormalities.
However, two patients (P2 and P7) reported by Trimis et al. (51)
and Soresina et al. (52) did not present neurological involvements
but both had a history of telangiectasia, frequent respiratory
infections, elevated serum IgM, and mild mutations. The
absence of neurological features makes many difﬁculties in the
diagnosis of the disease, especially in this type of variant, as
patients might lead to being misdiagnosed as hyper IgM
syndrome (HIgM). It has been postulated that other genetic
modiﬁers or environmental factors can affect the neurological
and clinical features of AT (52) as classical AT were observed in
the close relatvies of two of our newly reported patients, most
likely with the same ATM mutations. Cerebellar ataxia and
extrapyramidal symptoms, similar to our 3 cases, were seen in
most of the reported atypical patients indicating that these patients
are vulnerable to both pathophysiologic mechanisms.
Dysarthria, as a most frequent cerebellar symptom (after ataxia),
has been reported in 80% of AT patients (53); however, our study
revealed a lower frequency of dysarthria in variant AT patients
(Cases 2 and 3 of the present study and 64% of previously reported
patients). In accordance with previous reports, the most common
extrapyramidal symptoms were dystonia and tremor in reported

reviewed 73 reported variant AT patients with atypical late-onset
ataxia in terms of clinical, immunological and genetic ﬁndings.
In contrast to currently reported cases, we found that biallelic
mild mutations mainly lead to an atypical phenotype with an
increased risk of cancer (47). Our study conﬁrms that disease
severity in variant AT is milder compared to the classical form.
Similar to what was observed in our cases, more than 70% of
reported patients were not wheelchair-bound at the last
examination, indicating unexpected slow progression in variant
AT patients. Wheelchair use as a result of progressive cerebellar
ataxia, presenting in early childhood, is a characteristic feature of
classical AT patients (4, 48). This is consistent with our ﬁndings
that even atypical patients with the severe phenotype
(wheelchair-bound) demonstrated a signiﬁcantly lower age of
presenting onset and ataxia onset than other groups.
Previous reports revealed that within variant atypical AT
patients, extrapyramidal movement disorders are dominating
presentation rather than cerebellar signs. Extrapyramidal
symptoms are commonly observed in predate ataxia in these
patients, and the later occurring ataxia is of mild to moderate
degree (7, 8). However, our study showed that in long follow-up
they can occur relative to the same extent. On the other hand,
Verhagen et al. (7) revealed that variant atypical AT patients
generally presents with extrapyramidal symptoms such as chorea
and resting tremor, respectively. We observed that tremor and
chorea after ataxia were the most frequent presenting
manifestation. Dystonia generally appears as a late manifestation
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variant AT (50). Carrillo et al. (54) reported that patients presenting
predominant dystonia tend to have a later onset and a milder disease
course. However, some studies observed the rare existence of
dystonia among adolescents and adult AT patients (55).
Nonetheless, it remains unclear at this time if the dystonic
presentation is related to a speciﬁc genotypic abnormality (54).
Chorea presented in 28% reviewed variant AT atypical patients; in
contrast, few studies reported chorea mostly in mild patients (7).
Mé neret et al. (50), did not ﬁnd chorea in any of their variant
atypical patients, suggested that myoclonic dystonia in patients who
were only assessed clinically can easily be mistaken for chorea. On
the other hand, as severe chorea may cover the presence of ataxia, it
should be considered that not all neurological signs indicate the
cerebellum as the central lesion (49). Apraxia, as a hallmark of
atypical AT, was appeared only in 25% of reported variant patients
(7, 56). However, there is no direct correlation between the severity
of eye movements and the severity of other neurologic
symptoms (53).
In imaging of variant atypical AT patients, cerebellar
morphology is often normal (5), though our study shows that
only 35% reported atypical patients did not have cerebellar
atrophy. However, a hypothesis suggested that some defects in
abnormal ATM function may lead to cerebellar atrophy (57).
Although multiple studies revealed that AT almost universally
affects the cerebellum, the integrity of other mechanisms such as
the anterior horn cells, basal ganglia, peripheral nerves, and
dorsal columns may be inﬂuenced heterogeneously by the
disease process (58, 59). Moreover, a signiﬁcant increase in the
frequency of cerebellar atrophy in the severe group demonstrate
the relationship between the cerebellar atrophy and its effect on
the walking ability of the patient; however, a relatively minor role
of cerebellar cortical volume in the immediate expression of the
neurodegeneration of AT has been reported (60).
Immunodeﬁciency with great variability is a characteristic
feature of 60%–80% of AT patients (49); however, it is rarely
observed in mild AT forms (7). As observed in the currently
reported 3 cases, about 38% of individuals had an
immunoglobulin deﬁciency, although most of them did not
present considerable clinical features suggesting immune system
dysfunction. It has been recognized that patients with ATM protein
expression have an ameliorated immunological phenotype
regardless of the presence or absence of residual kinase activity
(8). On the other hand, patients with no kinase activity present
signiﬁcantly more severe immunological phenotypes than those
with low levels of ATM activity (61). Besides, Van Os et al. (9)
reported no correlation between the immune defects and
expression of the ATM protein in AT. One possible mechanism
of immunodeﬁciency has been proposed to small thymuses with
poorly developed Hassal’s corpuscles in AT patients (62).
Moreover, it has been reported that defective DNA repair and
high levels of ROS production following dysfunction of ATM leads
to the induction of apoptosis and cell death in ATM-deﬁcient T cells
(4). In terms of immunodeﬁciency, approximately 10% of AT
patients exhibit the HIgM phenotype in which respiratory
infections manifest at a very young age (63). Since neurological
symptoms in these patients could be mild or absent, this could lead
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to misdiagnosis of variant AT with HIgM syndrome (64). Similar to
cases 1 and 2 in the present study 10% of variant patients presented
HIgM phenotype, as all were homozygous for a truncating mutation
predicting the absence of ATM protein. The HIgM phenotype of
AT is also associated with autoimmunity and cutaneous
granulomatous disease (65–68). Except for case 3 of the present
study, all reported patients with autoimmunity and cutaneous
granuloma presented with HIgM phenotype along with
splenomegaly. The etiology of these complications is not welldeﬁned, but it seems that reduced regulatory T cells and increased
ratios of CD21−/low B cells, as well as disturbed naïve T and B cells
along with splenomegaly, could be attributed to these patients (64–
66). However, in our 3 evaluated cases, despite a decrease in naïve
and regulatory T cells, nobody had an increase in CD21−/low B cells.
Our ﬁndings conﬁrm our previous observation in which AT
patients with class switch recombination (CSR) defect had lower
CD21−/low B cells compared to remaining (CSR Normal) patients
(13). On the other hand, it has been reported that an abundance of
CD21−/low B cells in AT patients is associated with an increase of
naïve B cell proliferation (69). Increased CD21−/low B cells and its
association with autoimmunity and splenomegaly have been
reported by in common variable immunodeﬁciency (CVID) (70,
71), however there are no other reports in AT patients to show an
increase of this subset in autoimmune disease.
Rearrangements of chromosomes 7 and 14 presented in most
reported variant AT patients in this study. Interestingly, the same
was true for all reported variant AT patients in the literature (72).
On the other hand, it has been postulated that chromosomal
translocation between chromosomes 7 and 14 that are associated
with Ig/TCR genes may be involved in Immunodeﬁciency in AT
patients (73). This is conﬁrming our data that the frequency of
immunodeﬁciency and karyotype abnormalities are relatively
associated among the groups. Also, by comparison, the
frequency of karyotype abnormalities and immunodeﬁciency
between our 3 groups, we demonstrated the inverse
relationship between the frequency of them with the severity of
neurological phenotypes, which indicates the severity of
neurological phenotypes are not associated with the occurrence
of karyotype abnormalities and immunodeﬁciency.
Among AT patients, the lifetime risk of malignancy is 10%–
38% (74, 75). Furthermore, Verhagen et al. reported that cancer
can occur later in the life of variant AT, which typically consists
of solid malignancies rather than lymphoid cancer (7, 8). In line
with the literature, 21% reported atypical patients who suffered
from malignancies presented mostly in adulthood with
predominately solid tumors. We found that about 85% of
individuals with malignancy had a missense mutation, which
can cause the production of a mutant ATM protein with retained
kinase activity. Our ﬁndings correspond with the results of Schon
et al. (47), indicating variant patients with a missense mutation
are almost ﬁvefold more at-risk to develop a malignancy.
Moreover, previous reports revealed p.Ala2067Asp and
p.Val2424Gly missense mutations as a high-risk cause of
malignancy (76, 77). The nature of the underlying ATM
mutation, which on the one hand does not protect against
cancer development or radiation damage, but on the other,
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allows ATM expression with sufﬁcient activity to protect against
severe neurodegeneration, has not been fully understood. Maybe
modifying genes/regulators affect these clinical and cellular
responses (78). Infection and malignancy are the main causes
of mortality in patients with AT (9). Our report revealed that
malignancies, instead of respiratory failure, were the main cause
of death in variant AT patients, which is similar to previous
reports (8).
Consistent with the expected notion, we found that more than
80% of individuals had a missense mutation, possibly causing
milder neurological features (7, 50). Although the correlation of
neurodegenerative phenotype and defect of ATM is unclear, the
hypothesis suggested that ATM protein expression may allow
neurons to initiate apoptosis pathways or repair damaged DNA
(79, 80). On the other hand, Verhang et al. (7) suggested that in
AT variant, a better-conserved function of the mitochondrion
due to less oxidative stress as a consequence of residual ATM
kinase activity can describe the milder clinical symptoms. They
also suggested that some splicing mutations with less ATM
protein expression and kinase activity may result in a more
severe phenotype rather than missense mutation. Besides, some
cases (P26 and P27) showed no ATM kinase activity associated
with the expressed protein despite ATM missense mutations and
reduced ATM protein expression. A more sensitive assay would
help detect low differential levels of ATM activity associated with
different ATM proteins, while there may be some activity
retained to cause milder features of the disease (47). Another
possible explanation is that missense mutation in the kinase
domain, may lead to a normal level of protein expression but not
functional (kinase-dead) protein (81).
Here, we show that similar to our 3 cases, approximately 9%
of variant AT patients with mild clinical phenotype can appear
with the presence of null ATM mutations (frameshift and
nonsense mutations causing truncation), leading to an absence
of ATM protein and no kinase activity. These observations raise
the possibility that the neuronal cells of these patients are affected
by a modifying gene leading to a compensatory pathway that
protects against the consequences of ATM loss (57). The rarity of
such patients probably indicates that the highly inﬂuential alleles
of such modiﬁer genes are rare (60). Rarely, patients with mild or
classical AT show a normal intensity of the ATM band on a
Western blot (82, 83); as our study revealed that 9% of variant
AT patients showed a normal ATM protein expression. One of
the limitations of our study is that we did not have extra access to
the material to check the level of ATM protein as well as its
activity in our patients. Our previous report also showed that
approximately 90% of AT patients with classical presentations
had a homozygous mutation (84); however, we found that more
than 60% of the reported variant AT patients had a compound
heterozygous mutation. However, we did not ﬁnd a signiﬁcant
genotype-phenotype association with regards to neurological
groups in the study overall, indicating an additional inﬂuence
of shared environmental factors or disease-modifying genes.
Future examination of newly identiﬁed ATM functions may
provide vital insights into the relationship between mutation and
phenotype (10, 85–89).
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CONCLUSION
There is no universally accepted deﬁnition of the variant AT
phenotype. The clinical spectrum of these atypically affected AT
patients may be similar, although the underlying causative ATM
mutations may be different. Our results support previous results
that AT is not only due to pure ataxia and may appear as only
different extrapyramidal signs or even normal neurological
symptoms. As they are likely to be under or misdiagnosed, early
diagnosis using newborn screening or unbiased next-generation
sequencing on suspected individuals is crucial considering the
increased risk of malignancies, the related higher risk for side
effects of radiation and certain chemotherapy regimens in cancer
treatment, genetic counseling, carrier detection within the affected
family, and prenatal diagnosis.
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Morbidity and Mortality From Ataxia-Telangiectasia are Associated With
ATM Genotype. J Allergy Clin Immunol (2011) 128:382–389. e1. doi: 10.1016/
j.jaci.2011.03.052
6. Moeini Shad T, Ranjouri M, Amirifar P. Clinical Manifestations in Iranian
Ataxia Telangiectasia Patients. Immunol Genet J (2020) 3:29–40. doi:
10.22034/igj.2020.224536.1034
7. Verhagen M, Abdo W, Willemsen M, Hogervorst F, Smeets D, Hiel J, et al.
Clinical Spectrum of Ataxia-Telangiectasia in Adulthood. Neurology (2009)
73:430–7. doi: 10.1212/WNL.0b013e3181af33bd
8. Verhagen MM, Last JI, Hogervorst FB, Smeets DF, Roeleveld N, Verheijen F,
et al. Presence of ATM Protein and Residual Kinase Activity Correlates With
the Phenotype in Ataxia-Telangiectasia: A Genotype–Phenotype Study. Hum
Mutat (2012) 33:561–71. doi: 10.1002/humu.22016
9. van Os NJ, Jansen AF, van Deuren M, Haraldsson A, van Driel NT, Etzioni A,
et al. Ataxia-Telangiectasia: Immunodeﬁciency and Survival. Clin Immunol
(2017) 178:45–55. doi: 10.1016/j.clim.2017.01.009
10. Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA,
Crawford TO, Lederman HM. Ataxia Telangiectasia: A Review. Orphanet J
rare Dis (2016) 11:159. doi: 10.1186/s13023-016-0543-7
11. Yazdani R, Abolhassani H, Kiaee F, Habibi S, Azizi G, Tavakol M, et al.
Comparison of Common Monogenic Defects in a Large Predominantly
Antibody Deﬁciency Cohort. J Allergy Clin Immunol Pract (2019) 7:864–78.
doi: 10.1016/j.jaip.2018.09.00
12. Abolhassani H, Kiaee F, Tavakol M, Chavoshzadeh Z, Mahdaviani SA,
Momen T, et al. Fourth Update on the Iranian National Registry of
Primary Immunodeﬁciencies: Integration of Molecular Diagnosis. J Clin
Immunol (2018) 38:816–32. doi: 10.1007/s10875-018-0556-1
13. Shad TM, Youseﬁ B, Amirifar P, Delavari S, Rae W, Kokhaei P, et al. Variable
Abnormalities in T and B Cell Subsets in Ataxia Telangiectasia. J Clin
Immunol (2021) 41:76–8. doi: 10.1007/s10875-020-00881-9
14. Aghamohammadi A, Rezaei N, Yazdani R, Delavari S, Kutukculer N,
Topyildiz E, et al. Consensus Middle East and North Africa Registry on
Inborn Errors of Immunity. J Clin Immunol (2021) 41:1339–51. doi: 10.1007/
s10875-021-01053-z
15. Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J,
et al. The European Society for Immunodeﬁciencies (ESID) Registry Working
Deﬁnitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy
Clin Immunol: In Pract (2019) 7:1763–70. doi: 10.1016/j.jaip.2019.02.004
16. Fang M, Abolhassani H, Lim CK, Zhang J, Hammarström L. Next Generation
Sequencing Data Analysis in Primary Immunodeﬁciency Disorders–Future
Directions. J Clin Immunol (2016) 36:68–75. doi: 10.1007/s10875-016-0260-y

Frontiers in Immunology | www.frontiersin.org

10

January 2022 | Volume 12 | Article 779502

Moeini Shad et al.

Atypical AT Patients

51. Trimis GG, Athanassaki C, Kanariou M, Giannoulia-Karantana A. Unusual
Absence of Neurologic Symptoms in a Six-Year Old Girl With AtaxiaTelangiectasia. J Postgraduate Med (2004) 50:270.
52. Soresina A, Meini A, Lougaris V, Cattaneo G, Pellegrino S, Piane M, et al.
Different Clinical and Immunological Presentation of Ataxia-Telangiectasia
Within the Same Family. Neuropediatrics (2008) 39:43–5. doi: 10.1055/s2008-1076736
53. Nissenkorn A, Ben-Zeev B. Ataxia Telangiectasia. In: Handbook of Clinical
Neurology. Amsterdam: Elsevier (2015). p. 199–214.
54. Carrillo F, Schneider SA, Taylor AMR, Srinivasan V, Kapoor R, Bhatia KP.
Prominent Oromandibular Dystonia and Pharyngeal Telangiectasia in
Atypical Ataxia Telangiectasia. Cerebellum (2009) 8:22. doi: 10.1007/s12311008-0055-7
55. Amromin GD, Boder E, Teplitz R. Ataxia-Telangiectasia With a 32 Year
Survival: A Clinicopathological Report. J Neuropathol Exp Neurol (1979)
38:621–43. doi: 10.1097/00005072-197911000-00007
56. Saviozzi S, Saluto A, Taylor A, Last J, Trebini F, Paradiso M, et al. A Late Onset
Variant of Ataxia-Telangiectasia With a Compound Heterozygous Genotype,
A8030G/7481insa. J Med Genet (2002) 39:57–61. doi: 10.1136/jmg.39.1.57
57. Worth PF, Srinivasan V, Smith A, Last JI, Wootton LL, Biggs PM, et al. Very
Mild Presentation in Adult With Classical Cellular Phenotype of Ataxia
Telangiectasia. Movement Disord (2013) 28:524–8. doi: 10.1002/mds.25236
58. Tavani F, Zimmerman R, Berry G, Sullivan K, Gatti R, Bingham P. AtaxiaTelangiectasia: The Pattern of Cerebellar Atrophy on MRI. Neuroradiology
(2003) 45:315–9. doi: 10.1007/s00234-003-0945-9
59. Sutton IJ, Last JI, Ritchie SJ, Harrington HJ, Byrd PJ, Taylor AMR. AdultOnset Ataxia Telangiectasia Due to ATM 5762ins137 Mutation
Homozygosity. Ann Neurology: Off J Am Neurological Assoc Child Neurol
Soc (2004) 55:891–5. doi: 10.1002/ana.20139
60. Alterman N, Fattal-Valevski A, Moyal L, Crawford TO, Lederman HM, Ziv Y,
et al. Ataxia-Telangiectasia: Mild Neurological Presentation Despite Null
ATM Mutation and Severe Cellular Phenotype. Am J Med Genet Part A
(2007) 143:1827–34. doi: 10.1002/ajmg.a.31853
61. Staples E, McDermott E, Reiman A, Byrd P, Ritchie S, Taylor A,
et al. Immunodeﬁciency in Ataxia Telangiectasia is Correlated Strongly
With the Presence of Two Null Mutations in the Ataxia Telangiectasia
Mutated Gene. Clin Exp Immunol (2008) 153:214–20. doi: 10.1111/j.13652249.2008.03684.x
62. Peterson RA, Kelly W, Good R. Ataxia-Telangiectasia its Association With a
Defective Thymus, Immunological-Deﬁciency Disease, and Malignancy.
Lancet (1964) 283:1189–93. doi: 10.1016/S0140-6736(64)91209-7
63. Noordzij JG, Wulffraat N, Haraldsson Á ., Meyts I, van’t Veer L, Hogervorst F,
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